Comparison of drug-susceptibility patterns and gene sequences associated with clarithromycin and azithromycin resistance in complex isolates and evaluation of the accumulation of intrinsic macrolide resistance Free

Abstract

complex (MABC) is an infectious agent associated with macrolide resistance and treatment failure.

Despite drug-susceptibility testing for MABC isolates including clarithromycin (CAM), long-term treatment with azithromycin (AZM) for MABC disease is recommended.

We compared phenotypic and genotypic resistance to AZM and CAM in clinical isolates and evaluated the accumulation of intrinsic macrolide resistance (AIM) and morphological changes by macrolides exposure.

Forty-nine isolates were characterized regarding (41) sequevars. Sequencing data were compared to the nucleotide sequence of and . The AIM MIC was performed in three reference strains and 15 isolates were randomized [each set of five isolates with subsp. (MAA) T28, MAA C28 and subsp. (MAM)].

The 49 isolates were distributed as 24 MAA T28, 5 MAA C28 and 20 MAM. The MIC values to CAM at day 3 in MAA T28, C28 and MAM were 1, 0.12 and 0.12 µg ml, while those at day 14 were 32, 0.5 and 0.12 µg ml, respectively. The AZM-MIC values at day 3 of the above isolates were 4, 0.25 and 0.5 µg ml, while those at day 14 were >64, 0.5 and 0.5 µg ml, respectively. Neither mutations in of MAA T28 with acquired resistance nor deletions in of MAA T28 without inducible resistance were observed . For AIM MIC, MAA T28 showed that the time-to-detection of AZM resistance was significantly faster over that of CAM (<0.05). Morphological changes were not determined in all isolates.

Our findings did not support the suggestion for the preferential use of AZM for, at least, MAA T28 disease due to the high-level MIC value and the increased AIM. The long duration of AZM-based treatment eventually may favour the emergence of isolates with a high-level of intrinsic resistance.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001326
2021-02-11
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/jmm/70/3/jmm001326.html?itemId=/content/journal/jmm/10.1099/jmm.0.001326&mimeType=html&fmt=ahah

References

  1. Lee M-R, Sheng W-H, Hung C-C, Yu C-J, Lee L-N et al. Mycobacterium abscessus complex infections in humans. Emerg Infect Dis 2015; 21:1638–1646 [View Article][PubMed]
    [Google Scholar]
  2. Tortoli E, Kohl TA, Brown-Elliott BA, Trovato A, Leão SC et al. Emended description of Mycobacterium abscessus, Mycobacterium abscessus subsp. abscessus and Mycobacterium abscessus subsp. bolletii and designation of Mycobacterium abscessus subsp. massiliense comb. nov. Int J Syst Evol Microbiol 2016; 66:4471–4479 [View Article][PubMed]
    [Google Scholar]
  3. Nash KA, Brown-Elliott BA, Wallace RJ. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae . Antimicrob Agents Chemother 2009; 53:1367–1376 [View Article][PubMed]
    [Google Scholar]
  4. Brown-Elliott BA, Vasireddy S, Vasireddy R, Iakhiaeva E, Howard ST et al. Utility of sequencing the erm(41) gene in isolates of Mycobacterium abscessus subsp. abscessus with low and intermediate clarithromycin MICs. J Clin Microbiol 2015; 53:1211–1215 [View Article][PubMed]
    [Google Scholar]
  5. Yoshida S, Tsuyuguchi K, Suzuki K, Tomita M, Okada M et al. Further isolation of Mycobacterium abscessus subsp. abscessus and subsp. bolletii in different regions of Japan and susceptibility of these isolates to antimicrobial agents. Int J Antimicrob Agents 2013; 42:226–231 [View Article][PubMed]
    [Google Scholar]
  6. Jeong SH, Kim S-Y, Huh HJ, Ki C-S, Lee NY et al. Mycobacteriological characteristics and treatment outcomes in extrapulmonary Mycobacterium abscessus complex infections. Int J Infect Dis 2017; 60:49–56 [View Article][PubMed]
    [Google Scholar]
  7. Koh W-J, Jeong B-H, Kim S-Y, Jeon K, Park KU et al. Mycobacterial characteristics and treatment outcomes in Mycobacterium abscessus lung disease. Clin Infect Dis 2017; 64:309–316 [View Article][PubMed]
    [Google Scholar]
  8. Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T. British thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax 201772
    [Google Scholar]
  9. Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline: executive summary. Clin Infect Dis 2020; 71:e1–e36 [View Article][PubMed]
    [Google Scholar]
  10. Kwak N, Dalcolmo MP, Daley CL, Eather G, Gayoso R et al. Mycobacterium abscessus pulmonary disease: individual patient data meta-analysis. Eur Respir J 2019; 54:1801991 11 07 2019 [View Article][PubMed]
    [Google Scholar]
  11. Woods GL, Wengenack NL, Lin G, Brown-Elliott BA, Cirillo DM et al. Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes Clinical and Laboratory Standards Institute; 2018 p M62
    [Google Scholar]
  12. Maurer FP, Castelberg C, Quiblier C, Böttger EC, Somoskövi A. Erm(41)-dependent inducible resistance to azithromycin and clarithromycin in clinical isolates of Mycobacterium abscessus . J Antimicrob Chemother 2014; 69:1559–1563 [View Article][PubMed]
    [Google Scholar]
  13. Tsai S-H, Lai H-C, Hu S-T. Subinhibitory doses of aminoglycoside antibiotics induce changes in the phenotype of Mycobacterium abscessus . Antimicrob Agents Chemother 2015; 59:6161–6169 [View Article][PubMed]
    [Google Scholar]
  14. Woods GL, Wengenack NL, Lin G, Brown-Elliott BA, Cirillo DM et al. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes Clinical Laboratory Standards Institute; 2018
    [Google Scholar]
  15. Yoshida S, Tsuyuguchi K, Kobayashi T, Tomita M, Inoue Y et al. Discrepancies between the genotypes and phenotypes of clarithromycin-resistant Mycobacterium abscessus complex. Int J Tuberc Lung Dis 2018; 22:413–418 [View Article][PubMed]
    [Google Scholar]
  16. Mougari F, Bouziane F, Crockett F, Nessar R, Chau F et al. Selection of resistance to clarithromycin in Mycobacterium abscessus subspecies. Antimicrob Agents Chemother 2017; 61: 27 12 2016 [View Article][PubMed]
    [Google Scholar]
  17. Pryjma M, Burian J, Kuchinski K, Thompson CJ. Antagonism between front-line antibiotics clarithromycin and amikacin in the treatment of Mycobacterium abscessus infections is mediated by the whiB7 gene. Antimicrob Agents Chemother 2017; 61:e01353–17 [View Article][PubMed]
    [Google Scholar]
  18. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6: molecular evolutionary genetics analysis version 6.0. Mol Biol Evol 2013; 30:2725–2729 [View Article][PubMed]
    [Google Scholar]
  19. Choi G-E, Shin SJ, Won C-J, Min K-N, Oh T et al. Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance. Am J Respir Crit Care Med 2012; 186:917–925 [View Article][PubMed]
    [Google Scholar]
  20. Bastian S, Veziris N, Roux A-L, Brossier F, Gaillard J-L et al. Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. Antimicrob Agents Chemother 2011; 55:775–781 [View Article][PubMed]
    [Google Scholar]
  21. Park J, Cho J, Lee C-H, Han SK, Yim J-J. Progression and treatment outcomes of lung disease caused by Mycobacterium abscessus and Mycobacterium massiliense . Clin Infect Dis 2017; 64:301–308 [View Article][PubMed]
    [Google Scholar]
  22. Guo Q, Chen J, Zhang S, Zou Y, Zhang Y et al. Efflux pumps contribute to intrinsic clarithromycin resistance in clinical, Mycobacterium abscessus isolates. Infect Drug Resist 2020; 13:447–454 [View Article][PubMed]
    [Google Scholar]
  23. van Ingen J, Boeree MJ, van Soolingen D, Mouton JW. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. Drug Resist Updat 2012; 15:149–161 [View Article][PubMed]
    [Google Scholar]
  24. Hurst-Hess K, Rudra P, Ghosh P. Mycobacterium abscessus WhiB7 regulates a species-specific repertoire of genes to confer extreme antibiotic resistance. Antimicrob Agents Chemother 2017; 61: 24 10 2017 [View Article][PubMed]
    [Google Scholar]
  25. Koh W-J, Jeon K, Lee NY, Kim B-J, Kook Y-H et al. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus . Am J Respir Crit Care Med 2011; 183:405–410 [View Article][PubMed]
    [Google Scholar]
  26. Luthra S, Rominski A, Sander P. The role of antibiotic-target-modifying and antibiotic-modifying enzymes in Mycobacterium abscessus drug resistance. Front Microbiol 2018; 9:2179 [View Article][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001326
Loading
/content/journal/jmm/10.1099/jmm.0.001326
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited Most Cited RSS feed